secwatch / observer
CUE Cue Biopharma, Inc.
CIK 0001645460 47 ready 8-Ks latest July 10, 2026, 5:29 PM ET RSS · JSON
Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (12)
Ready 8-Ks 47
Latest filing July 10, 2026, 5:29 PM ET
Top materiality 0.90
Event mix other_material ×17 · leadership ×14 · earnings ×8
Sentiment 9 pos · 2 neg · 36 neu
Latest earnings reported 2026-Q1
Executive change recent →
SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for CUE

Highest-materiality recent filing

Cue Biopharma inks collaboration with Boehringer Ingelheim for B cell depletion; $12M upfront

April 14, 2025, 7:59 PM ET other material materiality 0.90 positive item 1.01

Read filing →

Executive changes

Departed

Patrick Verheyen

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Peter Kiener

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Appointed

Daniel Camardo

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Viola Meehan

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Michael Meluzio

Vice President, Principal Accounting Officer
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.
Appointed

Sumita Ray

Chief Legal & Compliance Officer and Corporate Secretary
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
Role change

Colin Sandercock

Senior Vice President, Intellectual Property
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Successor
Sumita Ray
Filed
June 2, 2026, 4:45 PM ET
Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.
Departed

Jill Broadfoot

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Frank Morich

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Appointed

Shao-Lee Lin

Member of the Board
CUE · Cue Biopharma, Inc.
Effective
2026-04-30
Filed
May 1, 2026, 7:59 PM ET
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
Appointed

Shao-Lee Lin

President and Chief Executive Officer
CUE · Cue Biopharma, Inc.
Effective
2026-04-30
Filed
May 1, 2026, 7:59 PM ET
On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026
Departed (interim)

Lucinda Warren

Interim President and Chief Executive Officer
CUE · Cue Biopharma, Inc.
Effective
2026-04-30
Successor
Shao-Lee Lin
Filed
May 1, 2026, 7:59 PM ET
Dr. Lin will succeed Lucinda Warren whose resignation as Interim President and Chief Executive Officer was effective as of April 30, 2026

Earnings & guidance

2026-Q1 EPS reported -$1.08 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

9 positive 2 negative 36 neutral

source · CUE on sec.gov